Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Magagnoli, M.
Right arrow Articles by Santoro, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Magagnoli, M.
Right arrow Articles by Santoro, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:959-960, 2003
© 2003 European Society for Medical Oncology

Letters to the Editor

Minidose warfarin is associated with a high incidence of International Normalized Ratio elevation during chemotherapy with FOLFOX regimen

M. Magagnoli, G. Masci, C. Carnaghi, P. A. Zucali, L. Castagna, E. Morenghi and A. Santoro

Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan, Italy

*E-mail: massimo.magagnoli@humanitas.it

The first 10% of the full text of this article appears below.

Randomized trials have demonstrated that the combination of 5-fluorouracil (5-FU) and folinic acid (FA) with oxaliplatin, the FOLFOX regimen, is highly active in metastatic colorectal cancer [1, 2]. In this regimen, 5–FU is administered as a continuous infusion requiring a central venous catheter (CVC) implant with its inherent complications [3], such as venous thromboembolism (VTE). Prophylaxis with low-dose heparin or oral anticoagulants is . . . [Full Text of this Article]

Acknowledgements


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
P. Debourdeau, D. Kassab Chahmi, G. Le Gal, I. Kriegel, E. Desruennes, M.-C. Douard, I. Elalamy, G. Meyer, P. Mismetti, M. Pavic, et al.
2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group
Ann. Onc., September 1, 2009; 20(9): 1459 - 1471.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Magagnoli, G. Masci, L. Castagna, E. Morenghi, and A. Santoro
High incidence of INR alteration in gastrointestinal cancer patients treated with mini-dose warfarin and 5-fluorouracil-based regimens
Ann. Onc., January 1, 2006; 17(1): 174 - 176.
[Full Text] [PDF]

Home page
 Ann OncolHome page
G. Giunta
Warfarin-5-FU interactions
Ann. Onc., January 1, 2006; 17(1): 176 - 176.
[Full Text] [PDF]

Home page
 JCOHome page
R. Camidge, B. Reigner, J. Cassidy, S. Grange, M. Abt, E. Weidekamm, and D. Jodrell
Significant Effect of Capecitabine on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Cancer
J. Clin. Oncol., July 20, 2005; 23(21): 4719 - 4725.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Magagnoli, L. Castagna, G. Masci, and A. Santoro
Low-Dose Warfarin Prophylaxis for Catheter-Associated Thrombosis in Cancer Patients. Can It Be Safely Associated with 5-Fluorouracil-Based Chemotherapy?
Oncologist, September 1, 2004; 9(5): 594 - 595.
[Full Text] [PDF]